Democrats are trying to convince voters that lawlessness under President Donald Trump is a major threat. However, past debates over crime and safety could undermine their message. Candidates who previously supported defunding the police, a demand that arose from protests following George Floyd's death in 2020, are now facing tough questions. Some Democratic leaders fear these views may harm their chances in upcoming elections. In Wisconsin, gubernatorial candidate Francesca Hong has softened her stance on police funding. In Michigan and New York, candidates have also distanced themselves from previous defunding positions. A Pew study shows voters are more concerned about the economy, but crime remains a key issue.

Agios Pharmaceuticals AGIO reported a loss of $1.69 per share for the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of $1.86. In the year-ago quarter, the company had incurred a loss of $1.93 per share.Total revenues for the quarter came in at $44.7 million, significantly beating the Zacks Consensus Estimate of $23 million. Revenues surged 259.3% year over year, primarily driven by continued strong growth in Pyrukynd sales and robust demand for Aqvesme since the U.S. commercial launch in January this year.The company’s lead drug, mitapivat, is marketed under two brand names in the United States, Pyrukynd and Aqvesme. While Pyrukynd is approved for the treatment of hemolytic anemia in adult patients with pyruvate kinase (PK) deficiency, Aqvesme is approved to treat anemia in adults with alpha- or beta-thalassemia.Aqvesme received approval in the United States in December 2025 and was subsequently launched in January 2026, following the implementation of its Risk Evaluation and Mitigation Strategy program. Agios reported a strong initial uptake, with 442 prescriptions written as of June 30, 2026.Outside the United States, mitapivat continues to be marketed as Pyrukynd for PK deficiency and thalassemia indications. In May, Pyrukynd received approval for thalassemia in the European Union. Agios’ partner, Avanzanite Bioscience B.V., will commercialize and distribute Pyrukynd across the European Economic Area, the United Kingdom and Switzerland.AGIO's Q2 Earnings in DetailThe top line entirely comprises product revenues from Pyrukynd and Aqvesme. Agios generated $40.9 million of product revenues in the United States, up 235.2% year over year, driven by strong early momentum of the U.S. commercial launch of Aqvesme for thalassemia.The company added $3.8 million from ex-U.S. territories, driven by anticipated demand for Pyrukynd following its approval for thalassemia in Europe, as well as continued steady early demand across the Gulf Cooperation Council countries.Research and development expenses increased by approximately 9.6% year over year to $100.8 million in the quarter. The increase was primarily driven by the $25.0 million upfront payment related to the licensing agreement with Oscotec for cevidoplenib.Selling, general and administrative expenses totaled $51.5 million, up around 12.4% year over year, driven by higher spending associated with the commercial launch of Aqvesme.As of June 30, 2026, cash, cash equivalents and marketable securities totaled $964.8 million compared with $1.0 billion as of March 31, 2026. Management expects its existing cash balance, together with anticipated product revenues, to be sufficient to support the potential launch of mitapivat in sickle cell disease (SCD) if approved and advance its clinical pipeline.AGIO’s 2026 GuidanceFor full-year 2026, Agios expects to generate $45 million to $50 million in U.S. sales from Pyrukynd for PK deficiency.The company reiterated that full-year operating expenses are expected to remain approximately flat compared with 2025, excluding the $25 million upfront payment related to the cevidoplenib in-licensing agreement recognized in the second quarter.AGIO's Recent Pipeline UpdatesBeyond the marketed indications, Agios is also developing mitapivat for sickle cell disease (SCD). Earlier this month, the FDA accepted its supplemental new drug application (sNDA) seeking approval for mitapivat in SCD. The sNDA was submitted under the FDA’s accelerated approval pathway in May. With the FDA granting a priority review to the sNDA, a decision from the regulatory body is expected on Nov. 1, 2026. If approved, mitapivat is likely to become the first oral PK activator to be approved for patients with SCD.Agios had been developing another candidate, tebapivat, a novel PK activator, for the treatment of lower-risk myelodysplastic syndromes (LR-MDS) and SCD in separate mid-stage studies. However, the company has discontinued the development of tebapivat across all indications following setbacks in the clinical programs.In June, the company halted the candidate's development for LR-MDS after a phase II dose-finding study failed to demonstrate sufficient clinical benefit, despite showing biological activity and a favorable safety profile. Subsequently, in July, Agios also discontinued the SCD program after phase II data failed to demonstrate meaningful clinical differentiation from existing PK activators. These decisions marked the complete termination of the tebapivat development program.Despite the earnings beat, shares of AGIO were down 6.4% on Thursday, likely due to investor concern about the loss of tebapivat as a pipeline asset, which narrowed the company's growth prospects and increased its reliance on mitapivat, with its upcoming FDA decision now serving as the key catalyst.Image Source: Zacks Investment ResearchYear to date, the stock has risen 20.4% compared with the industry’s 3.6% growth.In early June, the company entered into an agreement with Oscotec, a South Korea-based biotech to in-license exclusive global rights to develop and commercialize cevidoplenib for immune thrombocytopenia (ITP).Cevidoplenib is a next-generation, late-stage, highly selective oral spleen tyrosine kinase inhibitor being developed for the treatment of patients with ITP, a rare autoimmune disorder characterized by low platelet counts and an elevated risk of bleeding.The agreement expands and diversifies Agios’ rare hematology portfolio by adding a potential treatment for ITP, with an estimated peak annual U.S. sales potential of up to $1 billion. Agios intends to advance cevidoplenib into a phase III study for ITP, with initiation expected in the first half of 2028. Per the agreement, Agios will fund all future development and commercialization costs associated with cevidoplenib.Agios Pharmaceuticals, Inc. Price, Consensus and EPS Surprise Agios Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Agios Pharmaceuticals, Inc. QuoteAGIO’s Zacks Rank & Stocks to ConsiderAgios currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the biotech sector are Harmony Biosciences HRMY and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy) and Neurocrine Biosciences NBIX, which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Over the past 90 days, earnings per share estimates for Harmony Biosciences have decreased from $3.34 to $3.30 for 2026. Over the same period, estimates for earnings per share increased from $3.79 to $3.87 for 2027. HRMY shares have lost 4.2% year to date.Harmony Biosciences missed on earnings in each of the trailing four quarters, delivering an average negative surprise of 25.16%.Over the past 90 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $1.50. Over the same period, EPS estimates for 2027 have risen to $5.31 from $2.91. LQDA shares have gained 151.7% year to date.Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.Over the past 90 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $8.00 to $9.09. Over the same period, EPS estimates for 2027 have increased from $9.48 to $10.81. NBIX shares have gained 30.8% year to date.Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

Core Laboratories Inc. CLB shares lost 47.1% in the past 6 months, in contrast to the Oil and Gas - Field Services industry’s rise of 3.9%. The shares of the company trades near a depressed level after a sharp selloff, but the investment case is not one-sided.Image Source: Zacks Investment ResearchThe stock offers a lower valuation, an asset-light model and improving technology adoption in Production Enhancement. Those positives must be weighed against falling earnings, geopolitical disruptions and limited near-term visibility.CLB Valuation Offers Upside With Execution RiskCLB’s share price of $10.35 compares with a 6-12 month price target of $13. The discount points to potential upside, but the longer-term view remains measured because operating recovery is still uneven.The stock trades at 0.79X forward 12-month sales, below its five-year median of 1.58X. Its trailing 12-month enterprise value-to-earnings before interest, taxes, depreciation and amortization multiple is 8.07X, also below the five-year median of 13.99X. Valuation is helpful, but stronger earnings execution is needed to make the discount more convincing.Image Source: Zacks Investment ResearchCore Laboratories Earnings Trends Stay UnevenCore Lab reported second-quarter 2026 adjusted earnings of 11 cents per share, above expectations of 8 cents. The result still declined from 19 cents in the year-ago quarter.Revenues fell 4.3% year over year to $124.6 million. Six-month operating income declined 44% to $11 million, while the current-year earnings estimate moved 4.5% lower over the past four weeks. SLB SLB, a larger oilfield technology peer, provides a relevant comparison for investors tracking offshore and international spending cycles. Halliburton Company HAL is another key services peer because its completions exposure overlaps with activity trends that influence CLB’s Production Enhancement business.CLB Cash Flow Supports Capital ReturnsCore Lab’s asset-light model remains central to the bull case. Low capital spending requirements and service-oriented operations help the company preserve cash during uneven industry conditions.Second-quarter free cash flow was $3.1 million. CLB also paid its quarterly dividend and repurchased 214,712 shares for $2.7 million, marking the seventh consecutive quarter of buybacks. Net debt decreased by $0.5 million during the quarter, but modest cash generation limits how quickly the company can reduce debt while funding dividends, repurchases and growth investments.Core Laboratories Catalysts Depend on RecoveryPotential catalysts remain tied to international exploration, offshore activity and wider use of proprietary technologies. Production Enhancement revenues rose 15% sequentially and 5% year over year, with operating margins reaching 12%.Core Lab secured work tied to projects in Australia, Namibia and Côte d’Ivoire. It also received regulatory approval to deploy SpectraStim and SpectraScan technologies in the United Arab Emirates. Still, Reservoir Description revenues fell 9% year over year, with margins of 5%, as Middle East activity, crude assay work and Russia-Ukraine-related sanctions pressured demand.CLB Scores Favor Value Over GrowthThe bottom line is that CLB looks cheaper after the selloff, but the stock still requires patience. A valuation reset alone does not remove earnings volatility or geopolitical exposure.The stock currently carries a Zacks Rank #4 (Sell). That rank tempers the appeal of a Value Score of B because weaker estimate revisions remain a concern.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.CLB also has a Growth Score of D, Momentum Score of C and VGM Score of D. The Style Scores suggest value characteristics are more favorable than growth and broader blended factors, but a weak Zacks Rank keeps the near-term setup cautious until revisions and operating momentum improve. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

International Business Machines Corporation IBM is leaning harder into software, hybrid cloud and artificial intelligence to make its revenue base more predictable. That shift is improving visibility, but it has not removed exposure to enterprise budget timing. The key investor question is whether recurring software streams and AI-related demand can offset near-term execution pressure and the uneven infrastructure cycle.IBM Builds Around Recurring Software RevenueSoftware is now the center of IBM’s business mix, accounting for 45.2% of GAAP revenues in second-quarter 2026. Segment revenues rose 5% in the quarter, while annual recurring revenue increased 8% to $24.6 billion.That recurring base matters because about 80% of annual software revenues come from subscription, consumption and support streams. IBM expects Software revenues to grow 6%-8% in 2026 and now targets 100 basis points of operating pretax margin expansion for the year.IBM Deepens Its Hybrid Cloud PortfolioIBM’s hybrid cloud strategy rests on Red Hat, OpenShift and a broader set of software assets that help enterprises manage applications, data and workloads across complex environments. Red Hat revenues increased 11% in the second quarter, and OpenShift annual recurring revenue reached $2.2 billion.HashiCorp and Confluent add more depth to that platform approach. HashiCorp posted record bookings, while Confluent remained on track after its first full quarter following the acquisition. Hybrid Cloud revenues rose 11%, and Data revenues advanced 18% on a constant-currency basis.Microsoft Corporation MSFT remains a relevant comparison because Azure Arc is designed to run Azure artificial intelligence and data services across cloud and edge environments. Oracle Corporation ORCL also competes in the same enterprise modernization theme through multicloud deployments and AI database services.IBM Consulting Turns AI Demand Into BacklogIBM’s Consulting business is showing that enterprise AI work is moving beyond small experiments. Consulting signings rose 6% to $5 billion in the second quarter, marking a second straight quarter of growth.Generative AI represented about half of Consulting signings and more than 30% of backlog. Revenue growth remained limited at 1% on a constant-currency basis, but segment profit rose 15.1%, and the margin expanded 160 basis points to 12.1%.That mix suggests AI demand is present, but conversion into revenue remains gradual. IBM still expects Consulting revenues to grow in the low-to-mid-single-digit range in 2026, supported by backlog quality and enterprise transformation work.IBM Faces Deal Timing and Mainframe PressureThe second quarter also showed why the growth outlook remains exposed to enterprise spending shifts. Total revenues rose 1.1% to $17.16 billion but missed the Zacks Consensus Estimate of $17.32 billion by 0.9%.The shortfall reflected delayed capital-expenditure-sensitive software transactions and weakness in IBM Z revenues. Clients redirected spending toward servers, storage and memory amid supply constraints and expected price increases.Infrastructure revenues declined 7% year over year, with IBM Z revenues down 42%. Transaction Processing revenues fell 9% on a constant-currency basis, showing that recurring software strength does not fully shield IBM from infrastructure and enterprise license agreement timing.IBM’s Mixed Scores Temper the Growth StoryIBM’s transformation remains credible, but the stock’s setup is not one-sided. Recurring software, Red Hat momentum, AI Consulting backlog and productivity actions support the case for steadier growth and margin leverage.At the same time, delayed deals, mainframe volatility and acquisition-related balance sheet demands keep the story balanced. IBM currently carries a Zacks Rank #3 (Hold), which points to a more neutral near-term earnings revision backdrop.The Value Score of C and Growth Score of C suggest neither valuation nor growth characteristics stand out strongly. The Momentum Score of D and VGM Score of D point to weaker share-price trends and limited near-term conviction across the combined style framework.For investors, IBM’s 2026 outlook depends on execution. The software-led model gives the company a stronger base than in past cycles, but the stock still needs clearer evidence that AI demand and recurring revenue can absorb deal timing and infrastructure pressure.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

OnPage Recognized in the Gartner® Hype Cycle™ for ITSM, 2026 EIN Presswire

Picture this: your calendar has been cleared, and your only plans for the night are getting to see all your Facebook Marketplace saves IRL. A dream date, right? Well, that was the concept behind Facebook’s VIP launch party last Thursday, July 23, to celebrate its Still Available residency in Los Angeles. The picture-perfect night was the kickoff to Facebook’s three-day experiential residency on Melrose Avenue, where Facebookhellip;read more raquo;

Ban policy incoming for Kahnawake Mohawk Council Facebook page Penticton Herald

Emerson Electric Co. EMR is likely to witness earnings and revenue growth when it reports third-quarter fiscal 2026 (ended June 2026) results on Aug. 4, after market close. The Zacks Consensus Estimate for revenues is pegged at $4.79 billion, indicating growth of 5.3% from the prior-year quarter’s figure.The consensus mark for earnings is pinned at $1.68 per share, which has remained steady in the past 60 days. The figure indicates a jump of 10.5% from the prior-year figure. The company’s bottom line matched the Zacks Consensus Estimate in the last reported quarter. EMR beat on earnings in two of the trailing four quarters and matched the mark in the other two, delivering an average surprise of 1.1%.Let’s see how things have shaped up for Emerson prior to the announcement.Factors Likely to Have Shaped EMR’s Quarterly PerformanceStrength across Emerson’s Intelligent Devices and Software and Systems groups is likely to have driven its performance in the fiscal third quarter. Solid momentum in the final control segment, driven by strength in power and LNG end markets, is likely to have benefited the top-line performance of its Intelligent Devices group in the fiscal third quarter. Robust growth across the Americas within the Sensors segment is also likely to aid the Intelligent Devices group’s results. For the fiscal third quarter, the Zacks Consensus Estimate for the group’s total sales is pegged at $2.64 billion, up 5.2% sequentially.Solid momentum in the Control Systems & Software segment, supported by strength in the power and life sciences end markets, is likely to have augmented the performance of the Software & Systems group. Also, strength in the aerospace & defense and semiconductor end markets has been aiding the Test & Measurement segment. For the fiscal third quarter, the consensus estimate for the group’s total sales is pegged at $1.59 billion, indicating a 6% rise from the previous quarter’s number.Robust growth across the Americas region is expected to have augmented the Safety & Productivity segment’s performance in the to-be-reported quarter.The company has remained focused on expanding its product offerings and market presence through buyouts. In March 2025, Emerson acquired the remaining shares of AspenTech, making it a wholly owned subsidiary. This move strengthened the company’s automation portfolio and enhanced its software-defined control capabilities. The buyout is expected to have boosted EMR’s top line in the quarter.However, rising costs and expenses owing to higher input costs and restructuring-related actions are likely to have affected EMR’s margin performance. Also, given the company’s substantial international operations, foreign currency headwinds are likely to have marred its margins and profitability.Emerson Electric Co. Price and EPS Surprise Emerson Electric Co. price-eps-surprise | Emerson Electric Co. QuoteEarnings WhispersOur proven model does not conclusively predict an earnings beat for Emerson this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as elaborated below.Earnings ESP: EMR has an Earnings ESP of -1.21% as the Zacks Consensus Estimate is pegged at $1.68 per share, higher than the Most Accurate Estimate of $1.66. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.Zacks Rank: EMR currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank stocks here.Stocks With the Favorable CombinationFerguson Enterprises Inc. FERG has an Earnings ESP of +1.22% and a Zacks Rank of 2 at present. The company is slated to release second-quarter 2026 results on Aug. 10.Ferguson’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 6.5%.Xometry, Inc. XMTR has an Earnings ESP of +66.67% and a Zacks Rank of 3 at present. The company is slated to release second-quarter 2026 results on Aug. 4.Xometry’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and matched the mark in one, the average surprise being 46.1%.Ball Corporation BALL has an Earnings ESP of +0.98% and a Zacks Rank of 3 at present. The company is slated to release second-quarter 2026 results on Aug. 4.Ball Corp.’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters while matching the mark in one, the average surprise being 3.8%. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

Is it of intrinsic value to ask why questions, even if we don't have any answer and it doesn't provide some other release, such as gratification that we are so clever? I definitely think we can have questions without answers, insofar as not all existing questions have good answers; we are under no obligation to accept the best answer we have. I was just thinking of generic why questions in everyday (social) life, why did my wife leave me, why doesn't god seem to love me, why do I hate my job, but in my imagination I probably base better questions on the same format.

Constellium SE CSTM and Ryerson Holding Corporation RYZ are leading players in the aluminum industry, supported by global operations and diversified business portfolios. With aluminum prices remaining elevated amid global economic uncertainty and persistent trade tensions, comparing these companies can help investors identify opportunities within the Zacks Metal Products - Distribution industry.Aluminum has become an attractive investment due to growing demand from electric vehicles, increased use of recycled aluminum and advancements in rechargeable batteries. Its demand is also rising as industries focus more on sustainability and efficiency. In addition, the recovery in global air travel has led aircraft manufacturers to increase production, driving higher demand for aluminum used in aircraft parts such as fuselages and wings.But which of these two stocks is better positioned to capitalize on these trends? Let’s compare their fundamentals to find out.The Case for ConstelliumConstellium’s Packaging & Automotive Rolled Products segment remains a key growth driver. In the second quarter of 2026, the segment’s revenues increased 36% year over year to $1.7 billion, driven by higher metal prices. It also benefited from supply shortages of automotive rolled products in North America, which supported the overall performance.Also, strength in the Aerospace & Transportation segment is aiding CSTM. The segment’s shipments increased 21% to 65 thousand metric tons in the second quarter of 2026, driven by higher shipments of aerospace and transportation, industry and defense (TID) rolled products. Revenues from the segment increased 38% to $680 million, supported by strong shipments and higher metal prices.The company’s Automotive Structures & Industry segment’s revenues grew 9% year over year to $458 million in the second quarter of 2026, supported by higher metal prices. Stable shipments compared with the prior-year quarter also supported the segment’s performance.CSTM also remains committed to rewarding its shareholders handsomely through share buybacks. For instance, it generated a solid free cash flow of $95 million in the first six months of 2026 and returned approximately $48 million to shareholders through share repurchases. It’s worth noting that in March 2026, the company’s board authorized a new share repurchase program of up to $300 million. The program became effective on May 21, 2026, and will remain in effect till Dec. 31, 2028.However, Constellium has been witnessing the impacts of escalating costs and expenses over time. In the second quarter of 2026, the cost of sales increased 23.3% year over year. Selling and administrative expenses also rose 14.8% in the quarter. The increase in operating expenses, if not controlled, might adversely impact the company’s margins in the quarters ahead.The Case for RyersonRyerson benefits from a diversified business structure that helps offset weakness in one end market with strength in others. The company is well-positioned to benefit from rising infrastructure spending, reshoring trends, increased fabrication outsourcing and ongoing manufacturing supply-chain restructuring. Also, its investments in expanding its non-ferrous polishing, buffing and grinding capabilities are expected to bolster the company's long-term position in the market.A key growth driver for Ryerson remains its aluminum product line. Aluminum prices and Midwest premiums increased during the second quarter of 2026, primarily due to supply disruptions in the Middle East. RYZ’s Aluminum shipments increased 10% year over year to 55,000 tons during the quarter. Revenues from the product line surged 41.8% to $434 million, aided by higher metal prices.In the same period, shipments from both the carbon steel and stainless steel product lines increased 67% and 45%, year over year, respectively. Also, revenues from these product lines grew 89.3% and 63.8%, respectively, due to an increase in average selling prices.In the second quarter, Ryerson’s total revenues increased 71.6% year over year to $2 billion, while total shipments rose 60.5% to 804,000 tons. For the third quarter of 2026, the company expects net sales of $1.87-$1.95 billion. Average selling prices are expected to remain flat or increase up to 2%.However, the company’s warehousing, delivery, selling, general and administrative expenses increased 58.7% year over year to $320.3 million in the second quarter. The increase mainly reflected the addition of Olympic Steel’s operating expenses and higher costs associated with the expanded revenue and shipment base.Also, high debt levels remain a concern for Ryerson. It exited the second quarter of 2026 with total debt of $955 million and net debt of $913 million, up $47 million and $30 million, respectively, from the first quarter of 2026. The increase reflected higher working capital requirements associated with increased revenues.How Does the Zacks Consensus Estimate Compare for CSTM & RYZ?The Zacks Consensus Estimate for CSTM’s 2026 sales and earnings per share (EPS) implies year-over-year growth of 30.6% and 84.9%, respectively. The company’s EPS estimates for 2026 have increased 6.3% over the past 30 days.Image Source: Zacks Investment ResearchWhile the consensus estimate for RYZ’s 2026 sales implies year-over-year growth of 53.9%, the same for EPS indicates an increase of 170.5%. The company’s EPS estimates remained steady over the past 30 days for 2026.Image Source: Zacks Investment ResearchPrice Performance and Valuation of CSTM & RYZIn the past six months, Constellium’s shares have surged 20.5%, while Ryerson stock has declined 8.6%.Image Source: Zacks Investment ResearchConstellium is trading at a forward 12-month price-to-earnings ratio of 9.42X compared with its median of 9.99X over the last five years. Ryerson is trading at a forward 12-month price-to-earnings ratio of 15.68X, above its median of 10.44X over the last five years.Image Source: Zacks Investment ResearchFinal TakeConstellium continues to witness strength across its key business segments, supported by favorable aluminum pricing. Also, its commitment to returning capital to shareholders augurs well for its long-term growth prospects. However, rising operating costs remain a concern for its margins.In contrast, Ryerson is benefiting from its diversified business model, robust momentum in its aluminum product portfolio and improving demand across steel categories, supported by higher metal prices. The company is well-positioned for continued growth, driven by healthy shipment volumes. However, increasing expenses and elevated debt levels continue to pose risks to its financial performance.Given these factors, CSTM seems a better pick for investors than RYZ currently. While Constellium carries a Zacks Rank #3 (Hold), RYZ currently has a Zacks Rank #5 (Strong Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

DexCom, Inc. DXCM reported second-quarter 2026 adjusted earnings per share (EPS) of 70 cents, which beat the Zacks Consensus Estimate of 61 cents by 14.8%. The company reported adjusted EPS of 48 cents per share in the prior-year quarter.Revenues increased 13.1% year over year to $1.31 billion and surpassed the consensus mark of $1.30 billion by 1.01%.DXCM registered GAAP net income per share of 64 cents, up from the year-ago quarter’s figure of 45 cents.Following better-than-expected results and raised guidance, shares of DXCM have risen 8.3% in today’s pre-market trading. The stock has gained 12.3% in the year-to-date period against an 11.7% decline in the industry. The broader S&P 500 Index increased 6.6% in the same period.Image Source: Zacks Investment ResearchDXCM's U.S. Business Delivers Solid GrowthU.S. revenues totaled $933.4 million, up 11% from the year-ago quarter. Growth was supported by strong new-patient additions, share capture and a sequential increase in new customer starts.Management noted that demand remained broad-based across patient categories. Dexcom also highlighted a substantial untapped opportunity, with roughly 9 million people in the United States already covered for continuous glucose monitoring but not yet using the technology.Dexcom's International Revenues Outpace U.S. GrowthInternational revenues increased 19% year over year to $375 million. On an organic basis, international sales advanced 16%, benefiting from reimbursement expansion and stronger adoption in markets such as France and Canada.The company also broadened its overseas product portfolio with the launch of Dexcom Flex in Germany. The 15-day sensor targets basal-insulin users and people with type 2 diabetes not using insulin in selected markets.Margin Analysis of DXCMAdjusted gross profit totaled $838.5 million, up 20.6% from the prior-year quarter’s level. DexCom reported an adjusted gross margin (as a percentage of revenues) of 64.1%, up 400 basis points year over year.Research and development expenses totaled $153 million, up 3.2% year over year. Selling, general and administrative expenses totaled $358.7 million, up 9.4% from the year-ago quarter.The company reported adjusted operating income of $328.3 million, up 48% from the prior-year period’s level. Adjusted operating margin (as a percentage of revenues) was 25.1%, up 590 basis points year over year.Financial Position of DexcomDXCM exited the second quarter with cash, cash equivalents and marketable securities worth $1.95 billion compared with $2.42 billion in the first quarter of 2026.Cumulative cash provided by operating activities at the end of the second quarter of 2026 was $794.8 million compared with $486.8 million a year ago.The company repurchased approximately $600 million of shares during the quarter under its $1 billion 2026 authorization and completed the acquisition of Nutrisense.DexCom, Inc. Price, Consensus and EPS Surprise DexCom, Inc. price-consensus-eps-surprise-chart | DexCom, Inc. QuoteDXCM Raises 2026 Revenue and Margin OutlookDXCM now expects 2026 revenues of $5.18-$5.25 billion compared with the previous range of $5.16-$5.25 billion. The updated guidance implies annual growth of 11-13% and reflects stronger organic growth expectations, partly offset by an anticipated $15 million foreign-exchange headwind in the second half.The company raised its adjusted gross margin forecast to approximately 64% from 63-64%. It also increased adjusted operating margin guidance to 23.5-24% from 23-23.5% and adjusted EBITDA margin guidance to 31.5-32% from 31-31.5%.Wrapping UpDexCom exited the second quarter of 2026 on a strong note, supported by solid revenue growth, continued margin expansion and sustained momentum across its CGM portfolio. The company advanced the rollout of the G7 15 Day system, which is now available to all adult G7 customers in the United States following integration for Tandem pump users, including Mobi. DexCom expects to convert nearly half of its U.S. customer base to the extended-wear system by the end of 2026.The company also achieved an important international milestone as Health Canada cleared G7 15 Day, marking the product’s first regulatory approval outside the United States. DexCom plans to launch the system in Canada during the second half of 2026 and expand it into additional international markets over time, supporting broader access and adoption.DexCom further strengthened its clinical positioning through the CONNECT randomized trial for people with type 2 diabetes not using insulin. Participants using DexCom CGM achieved a 1.6-percentage-point A1C improvement, spent more than five additional hours per day in the target glucose range and recorded median device usage of 97% over 26 weeks. Looking ahead, the company remains focused on expanding access, advancing product innovation and sustaining long-term growth across global CGM markets.DXCM’s Zacks Rank & Other Stocks to ConsiderDXCM currently carries a Zacks Rank #2 (Buy).Some other top-ranked stocks in the broader medical space are McKesson MCK, Phibro Animal Health PAHC andCardinal Health CAH.McKesson carries a Zacks Rank #2 at present and has an estimated long-term growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.09%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.McKesson’s shares have gained 8.8% against the industry’s 12.7% decline in the year-to-date period.Phibro Animal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.25%.Phibro Animal Health stock has climbed 44.2% against the industry’s 17.1% decline in the year-to-date period.Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.Cardinal Health’s shares have lost 2.6% compared with the industry’s 3.1% decline in the year-to-date period. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

Elon Musk’s super PAC plans major spending push in Maine Senate race WABI

Instagram-Savvy `Cockroaches’ Spur India Pivot in Blow to Modi Bloomberg.com

Thank you, Allan, for the Windows version that I've played with. Looks good. I'm going to try the *nix version in a sandbox - might finally flatten my W10(7) laptop for Debian. GSAK was the holdup.p.s. Same Allan spelling here, unusual!

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Innodata Inc (INOD). This company, which is in the Zacks Engineering - R and D Services industry, shows potential for another earnings beat.When looking at the last two reports, this company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 121.06%, on average, in the last two quarters.For the last reported quarter, Innodata Inc came out with earnings of $0.42 per share versus the Zacks Consensus Estimate of $0.13 per share, representing a surprise of 223.08%. For the previous quarter, the company was expected to post earnings of $0.21 per share and it actually produced earnings of $0.25 per share, delivering a surprise of 19.05%.Price and EPS SurpriseFor Innodata Inc, estimates have been trending higher, thanks in part to this earnings surprise history. And when you look at the stock's positive Zacks Earnings ESP (Expected Surprise Prediction), it's a great indicator of a future earnings beat, especially when combined with its solid Zacks Rank.Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.Innodata Inc currently has an Earnings ESP of +17.65%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #1 (Strong Buy) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on August 6, 2026.With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss.Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

Elon Musk confirms new data center development in Whitehaven localmemphis.com

Aliens are trending right now. At least the topic of alien life. It’s in the news, it’s in our movie theaters, and even the U.S. government is getting in on the action as it releases troves of documents related to unexplained phenomena and the search for extraterrestrial life. But here’s a question that isn’t getting explored as much as others: If we do find alien life, will that alien life support the case for intelligent design or an evolutionary origin of life? On this episode of ID The Future, host Andrew McDiarmid welcomes Dr. Casey Luskin to the show to discuss this intriguing topic and the implications for intelligent design and evolution. Source

What is McDowell's response, or would be his response, to Davidson's challenge put forth in his paper, Action, Reason, and Causes for ant-causalist in action explanation? Is McDowell an anti-causalist?

Why did the Police Shot an Instagram Thug? Protecting Women or Marking Its Territory? IranWire